Journey Medical (DERM) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed Journey Medical (DERM) over the past year, losing 7.6% versus a loss of 20.9%. Yarrow Bioscience is the larger company by market cap ($184.9 million vs $167.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | YARW |
|---|---|---|
| Share price | $5.95 | $19.87 |
| Market cap | $167.94M | $184.88M |
| 1-day change | 0.00% | +5.83% |
| YTD return | -22.83% | -31.48% |
| 1-year return | -20.88% | -7.58% |
| 5-year return | — | -98.19% |
| EPS (TTM) | $-0.22 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.56 | $46.95 |
| 52-week low | $4.31 | $16.05 |
| Distance from 52-week high | -37.73% | -57.68% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +131.09% | +186.86% |
| Average volume | 184.01K | 88.98K |
| Shares outstanding | 22.22M | 9.30M |
| Employees | 58 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YARW has outperformed DERM by 13.3 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
DERM vs YARW FAQ
Which is bigger, Journey Medical or Yarrow Bioscience?
Yarrow Bioscience (YARW) is larger, with a market capitalization of $184.88M compared with $167.94M for Journey Medical (DERM).
Which stock has performed better over the past year, DERM or YARW?
YARW returned -7.58% over the past 12 months, compared with -20.88% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.